Treatment of snakebite in Australia

The current evidence base and questions requiring collaborative multicentre prospective studies

    Research output: Contribution to journalArticleResearchpeer-review

    Abstract

    Despite the wealth of anecdotes and case reports there are fundamental questions of management of snakebite in Australia that remain unresolved or for which the current evidence is limited. The efficacy in the field, potential limitations and possibility of improvements in pressure immobilisation first aid need objective studies in humans. Optimal bandage sizes, stretch and pressure for different sized limbs need further evaluation, as does the use of pressure pads. Better definitions of specific clinical envenoming syndromes attributable to individual snake species are required, including elucidation of within-genus variations, similarities and differences. Venom studies suggest this is especially important for species within the brown snake (Pseudonaja) and death adder (Acanthophis) genera. Appropriate antivenom types, doses and dosing intervals for individual snake species should be more formally studied in patients. Especially important are confirmation of the need for higher doses of brown snake antivenom, while possibly limiting unnecessarily high doses, confirmation of the critical importance of early antivenom use to prevent pre-synaptic neurotoxicity in Taipan and tiger snake bites and ascertainment of whether larger doses of antivenom are unhelpful in Taipan bites after specified time delays. Confirmation of clinical efficacy and dosing recommendations for use of tiger snake (Notechis) antivenom in envenoming from Australian copperhead (Austrelaps spp.), broad headed (Hoplocephalus spp.) and rough-scaled snakes (Tropidechis carinatus) also require formal study in patients. Other examples of clinical relevance of cross-specificity of current and future monospecific antivenoms and whether there are geographical variations in antivenom responses within species will require elucidation. Prospective multicentre collaborative studies with predefined data collection and serial venom level assays are proposed as the way forward in Australia to help resolve therapeutic uncertainties and to establish a firmer evidence base for best-practice treatment guidelines for Australasian elapid snakebite. � 2006 Elsevier Ltd. All rights reserved.
    Original languageEnglish
    Pages (from-to)941-956
    Number of pages16
    JournalToxicon
    Volume48
    Issue number7
    Publication statusPublished - 2006

    Fingerprint

    Antivenins
    Snake Bites
    Snakes
    Multicenter Studies
    Prospective Studies
    Venoms
    Practice Guidelines
    Pressure
    Therapeutics
    Agkistrodon
    Anecdotes
    Tigers
    First Aid
    Adders
    Bites and Stings
    Bandages
    Immobilization
    Uncertainty
    Assays
    Time delay

    Cite this

    @article{e88fd39f339a4ae794fd37e06543e413,
    title = "Treatment of snakebite in Australia: The current evidence base and questions requiring collaborative multicentre prospective studies",
    abstract = "Despite the wealth of anecdotes and case reports there are fundamental questions of management of snakebite in Australia that remain unresolved or for which the current evidence is limited. The efficacy in the field, potential limitations and possibility of improvements in pressure immobilisation first aid need objective studies in humans. Optimal bandage sizes, stretch and pressure for different sized limbs need further evaluation, as does the use of pressure pads. Better definitions of specific clinical envenoming syndromes attributable to individual snake species are required, including elucidation of within-genus variations, similarities and differences. Venom studies suggest this is especially important for species within the brown snake (Pseudonaja) and death adder (Acanthophis) genera. Appropriate antivenom types, doses and dosing intervals for individual snake species should be more formally studied in patients. Especially important are confirmation of the need for higher doses of brown snake antivenom, while possibly limiting unnecessarily high doses, confirmation of the critical importance of early antivenom use to prevent pre-synaptic neurotoxicity in Taipan and tiger snake bites and ascertainment of whether larger doses of antivenom are unhelpful in Taipan bites after specified time delays. Confirmation of clinical efficacy and dosing recommendations for use of tiger snake (Notechis) antivenom in envenoming from Australian copperhead (Austrelaps spp.), broad headed (Hoplocephalus spp.) and rough-scaled snakes (Tropidechis carinatus) also require formal study in patients. Other examples of clinical relevance of cross-specificity of current and future monospecific antivenoms and whether there are geographical variations in antivenom responses within species will require elucidation. Prospective multicentre collaborative studies with predefined data collection and serial venom level assays are proposed as the way forward in Australia to help resolve therapeutic uncertainties and to establish a firmer evidence base for best-practice treatment guidelines for Australasian elapid snakebite. � 2006 Elsevier Ltd. All rights reserved.",
    keywords = "snake venom antiserum, abdominal pain, article, Australia, bleeding, clinical feature, collapse, delayed neurotoxicity, demography, disease simulation, drug efficacy, drug megadose, emergency care, envenomation, evidence based medicine, fatality, first aid, headache, human, immobilization, lymph node pain, lymphoscintigraphy, neurotoxicity, nonhuman, priority journal, snake, snakebite, species identification, vomiting, Adult, Animals, Antivenins, Child, First Aid, Humans, Immobilization, Pressure, Snake Bites, Time Factors, Acanthophis, Acanthophis antarcticus, Austrelaps, Austrelaps superbus, Elapidae, Hoplocephalus, Notechis, Pseudonaja, Serpentes, Spilotes pullatus pullatus, Storeria dekayi, Tropidechis carinatus",
    author = "Bart Currie",
    year = "2006",
    language = "English",
    volume = "48",
    pages = "941--956",
    journal = "Toxicon",
    issn = "0041-0101",
    publisher = "Elsevier",
    number = "7",

    }

    Treatment of snakebite in Australia : The current evidence base and questions requiring collaborative multicentre prospective studies. / Currie, Bart.

    In: Toxicon, Vol. 48, No. 7, 2006, p. 941-956.

    Research output: Contribution to journalArticleResearchpeer-review

    TY - JOUR

    T1 - Treatment of snakebite in Australia

    T2 - The current evidence base and questions requiring collaborative multicentre prospective studies

    AU - Currie, Bart

    PY - 2006

    Y1 - 2006

    N2 - Despite the wealth of anecdotes and case reports there are fundamental questions of management of snakebite in Australia that remain unresolved or for which the current evidence is limited. The efficacy in the field, potential limitations and possibility of improvements in pressure immobilisation first aid need objective studies in humans. Optimal bandage sizes, stretch and pressure for different sized limbs need further evaluation, as does the use of pressure pads. Better definitions of specific clinical envenoming syndromes attributable to individual snake species are required, including elucidation of within-genus variations, similarities and differences. Venom studies suggest this is especially important for species within the brown snake (Pseudonaja) and death adder (Acanthophis) genera. Appropriate antivenom types, doses and dosing intervals for individual snake species should be more formally studied in patients. Especially important are confirmation of the need for higher doses of brown snake antivenom, while possibly limiting unnecessarily high doses, confirmation of the critical importance of early antivenom use to prevent pre-synaptic neurotoxicity in Taipan and tiger snake bites and ascertainment of whether larger doses of antivenom are unhelpful in Taipan bites after specified time delays. Confirmation of clinical efficacy and dosing recommendations for use of tiger snake (Notechis) antivenom in envenoming from Australian copperhead (Austrelaps spp.), broad headed (Hoplocephalus spp.) and rough-scaled snakes (Tropidechis carinatus) also require formal study in patients. Other examples of clinical relevance of cross-specificity of current and future monospecific antivenoms and whether there are geographical variations in antivenom responses within species will require elucidation. Prospective multicentre collaborative studies with predefined data collection and serial venom level assays are proposed as the way forward in Australia to help resolve therapeutic uncertainties and to establish a firmer evidence base for best-practice treatment guidelines for Australasian elapid snakebite. � 2006 Elsevier Ltd. All rights reserved.

    AB - Despite the wealth of anecdotes and case reports there are fundamental questions of management of snakebite in Australia that remain unresolved or for which the current evidence is limited. The efficacy in the field, potential limitations and possibility of improvements in pressure immobilisation first aid need objective studies in humans. Optimal bandage sizes, stretch and pressure for different sized limbs need further evaluation, as does the use of pressure pads. Better definitions of specific clinical envenoming syndromes attributable to individual snake species are required, including elucidation of within-genus variations, similarities and differences. Venom studies suggest this is especially important for species within the brown snake (Pseudonaja) and death adder (Acanthophis) genera. Appropriate antivenom types, doses and dosing intervals for individual snake species should be more formally studied in patients. Especially important are confirmation of the need for higher doses of brown snake antivenom, while possibly limiting unnecessarily high doses, confirmation of the critical importance of early antivenom use to prevent pre-synaptic neurotoxicity in Taipan and tiger snake bites and ascertainment of whether larger doses of antivenom are unhelpful in Taipan bites after specified time delays. Confirmation of clinical efficacy and dosing recommendations for use of tiger snake (Notechis) antivenom in envenoming from Australian copperhead (Austrelaps spp.), broad headed (Hoplocephalus spp.) and rough-scaled snakes (Tropidechis carinatus) also require formal study in patients. Other examples of clinical relevance of cross-specificity of current and future monospecific antivenoms and whether there are geographical variations in antivenom responses within species will require elucidation. Prospective multicentre collaborative studies with predefined data collection and serial venom level assays are proposed as the way forward in Australia to help resolve therapeutic uncertainties and to establish a firmer evidence base for best-practice treatment guidelines for Australasian elapid snakebite. � 2006 Elsevier Ltd. All rights reserved.

    KW - snake venom antiserum

    KW - abdominal pain

    KW - article

    KW - Australia

    KW - bleeding

    KW - clinical feature

    KW - collapse

    KW - delayed neurotoxicity

    KW - demography

    KW - disease simulation

    KW - drug efficacy

    KW - drug megadose

    KW - emergency care

    KW - envenomation

    KW - evidence based medicine

    KW - fatality

    KW - first aid

    KW - headache

    KW - human

    KW - immobilization

    KW - lymph node pain

    KW - lymphoscintigraphy

    KW - neurotoxicity

    KW - nonhuman

    KW - priority journal

    KW - snake

    KW - snakebite

    KW - species identification

    KW - vomiting

    KW - Adult

    KW - Animals

    KW - Antivenins

    KW - Child

    KW - First Aid

    KW - Humans

    KW - Immobilization

    KW - Pressure

    KW - Snake Bites

    KW - Time Factors

    KW - Acanthophis

    KW - Acanthophis antarcticus

    KW - Austrelaps

    KW - Austrelaps superbus

    KW - Elapidae

    KW - Hoplocephalus

    KW - Notechis

    KW - Pseudonaja

    KW - Serpentes

    KW - Spilotes pullatus pullatus

    KW - Storeria dekayi

    KW - Tropidechis carinatus

    M3 - Article

    VL - 48

    SP - 941

    EP - 956

    JO - Toxicon

    JF - Toxicon

    SN - 0041-0101

    IS - 7

    ER -